| SANOFI |
SANOFI |
90%
|
we granted Sanofi an exclusive license under certain intellectual property rights to commercialize losmapimod for the treatment of FSHD outside of the United States. |
| BMY |
Bristol-Myers Squibb Company |
72%
|
nable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. As of December 31, 2024, … |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from FULC graph: nable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned leve… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from FULC graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from FULC graph: Reciprocal relationship from BMYM… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
nable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. As of December 31, 2024, … |
| CAMP |
CAMP4 THERAPEUTICS CORPORATION |
72%
|
nce with the agreement, the termination became effective on , which is 120 days following the date of receipt of the notice by the Company. F- 20 million, which was allocated to the performance oblig… |
| CAMP |
CAMP4 THERAPEUTICS CORPORATION |
72%
|
Reciprocal relationship from CAMP graph: Reciprocal relationship from FULC graph: Reciprocal relationship from CAMP graph: Reciprocal relationship from FULC graph: Reciprocal relationship from CAMP g… |
| SNYNF |
Sanofi |
72%
|
nce with the agreement, the termination became effective on , which is 120 days following the date of receipt of the notice by the Company. F- 20 million, which was allocated to the performance oblig… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from FULC graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from FULC graph: nce with the agreement, the termi… |
| COMPANY-INCORPORATED |
COMPANY-INCORPORATED |
62%
|
llion decrease in stock-based compensation expense; • $1.0 million of decreased facility costs primarily as a result of the expiration of our lease agreement for office space at 125 Sidney Street; an… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
reputation, customer trust, business, results of operations and financial condition could be adversely affected. Because the techniques used by threat actors who may attempt to penetrate and sabotage… |
| FULCRUM-THERAPEUTICS-SECURITIES-CORP |
FULCRUM-THERAPEUTICS-SECURITIES-CORP |
62%
|
th genetically-defined rare diseases in areas of high unmet medical need. The Company is subject to a number of risks similar to other companies in the biotechnology industry, including, but not limi… |
| MEDICAL-CENTER-CORPORATION |
MEDICAL-CENTER-CORPORATION |
62%
|
may be reduced in specified circumstances. The MyoKardia Collaboration Agreement continues on a country-by-country and product-by-product basis until the last to expire royalty term for a product, at… |
| PRESENTATION-FULCRUM-THERAPEUTICS-INC |
PRESENTATION-FULCRUM-THERAPEUTICS-INC |
62%
|
n received during the reporting period requires judgment because the timing and pattern of vendor invoicing does not correspond to the progress of the studies or extent of services provided and there… |
